ClinicalTrials.gg
CompletedNCT01527734Updated Feb 8, 2012

Comparison Study of Liquid and Lyophilized Formulations of Subcutaneous Tetrodotoxin (TTX) in Healthy Volunteers

A Phase 1 interventional study of Tetrodotoxin and placebo in Healthy, sponsored by Wex Pharmaceuticals Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-02-08.

Sponsored by Wex Pharmaceuticals Inc. · Phase 1, Interventional, and Screening

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The study design is a randomized, double-blind, placebo-controlled, parallel-group, dose comparison with a open-label, crossover, formulation comparison.

02

Conditions studied

  • Healthy

Keywords

  • Comparison study
03

In context

Lead sponsor

Wex Pharmaceuticals Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Normal renal function

Exclusion criteria

Exclusion Criteria:

  • History of multiple drug allergies
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Screening
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
44 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: placebo

  • Experimental
    Tetrodotoxin, TTX

    Drug: Tetrodotoxin

Interventions

  • 15ug and 30ug once or twice a day for 1 or 2 days.

  • Drugplacebo

    1ml once or twice a day for 1 or 2 days.

06

What researchers measure

Primary outcomes

  1. Compare plasma and urine PK profiles of TTX following doses of Lyophilized and Injectable Liquid TTX

    PK timepoints occurred at 0,0.33,0.67,1, 1.5,2,4,6,8,10,12,14 and 24 hours after first dose on Days 1 \& 2. Liquid and Lyophilized formulations will be assessed using ANOVA of the T-R ratio based on log-transformed AUC and Cmax values.

    Time frame: 26 timepoints over 48 hours

Secondary outcomes

  1. Assess the safety and tolerability of TTX following the administration of Lyophilized and Liquid TTX

    Safety was assessed through the collection of AE's, concomitant medications, clinical laboratory assessments, neurological assessments and vital signs. Where summary statistics are presented, these will include n, mean, standard deviation, median, minimum, and maximum.

    Time frame: signage of the ICF to Day 10

07

Study locations

1 site
  • Comprehensive Clinical Research
    Tacoma, Washington 98418, United States
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011 and a primary completion of Jan 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2012
First posted
Feb 7, 2012
Start
Dec 2011
Primary completionActual
Jan 2012
Last update
Feb 8, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01527734
Lead sponsor
Wex Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Feb 7, 2012
Start date
Dec 2011
Primary completion
Jan 2012
Last update
Feb 8, 2012
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tetrodotoxin

Start the discussion